Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod IV in AChR-Ab Seronegative Generalized Myasthenia Gravis
NCT06298552Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Antibody Fragments
- Countries
- 22
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Apr 2024; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06298552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298552.